Fundraising FoxRapamycin Holdings
San Antonio, US · Founded 2012 · Delaware corporation · 1 known investors
Find your way into Rapamycin Holdings
Sign up to see every warm intro you have to Rapamycin Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rapamycin Holdings team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
RH
Randy H GoldsmithFounder, Director, Senior AdvisorRandy Goldsmith served as Investor in Residence at the Texas Technology Development Center in San Antonio and previously held leadership roles including President and CEO of the Mississippi Technology Alliance, managing director of the Oklahoma Technology Development Corp, and director of the Oklahoma Manufacturing Alliance for Excellence, with earlier experience establishing a technology commercialization program at the NASA Mid-continent Regional Technology Transfer Center.
MH
Mark HorseySecretary and Chief Financial Officer
Board
SD
Stephen DufilhoChairman of the Board of Directors
Investors · 1
UT Horizon FundreportedAustin
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 1 of 6 rounds · 2013–2019
▶$7MofferedJun 2019 · PharmaceuticalsRule 506(c)
▶$7MofferedJun 2019 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Stephen DufilhoDirector
- Spangler Vaughn CaroleExecutive Officer
- Mark HorseyExecutive Officer
- Offering amount
- $7M
- Minimum investment
- $100K
- Proceeds to insiders
- $450K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$1.5MofferedFeb 2018 · PharmaceuticalsRule 506(c)
▶$1.5MofferedFeb 2018 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Stephen DufilhoDirector
- Mark HorseyExecutive Officer
- Hargrove DanExecutive Officer
- Offering amount
- $1.5M
- Minimum investment
- $100K
- Proceeds to insiders
- $250K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$3.5MofferedAug 2017 · PharmaceuticalsRule 506(c)
▶$3.5MofferedAug 2017 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Stephen DufilhoDirector
- Mark HorseyExecutive Officer
- Hargrove DanExecutive Officer
- Offering amount
- $3.5M
- Minimum investment
- $100K
- Proceeds to insiders
- $250K
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
▶$2MofferedApr 2016 · PharmaceuticalsRule 506(c)
▶$2MofferedApr 2016 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Randy H GoldsmithExecutive Officer, Director
- Stephen DufilhoDirector
- Mark HorseyExecutive Officer
- Offering amount
- $2M
- Minimum investment
- $100K
- Proceeds to insiders
- $200K
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
▶$2.5MofferedJul 2014 · PharmaceuticalsRule 506(c)
▶$2.5MofferedJul 2014 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Stephen DufilhoDirector
- Randy H GoldsmithExecutive Officer, Director
- Mark HorseyExecutive Officer
- Offering amount
- $2.5M
- Minimum investment
- $100K
- Proceeds to insiders
- $120K
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
▶$1.4MraisedFeb 2014 · 18 investors · PharmaceuticalsRule 506(c)
▶$1.4MraisedFeb 2014 · 18 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Mark HorseyExecutive Officer
- Randy H GoldsmithExecutive Officer, Director
- Stephen DufilhoDirector
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Minimum investment
- $44.1K
- Proceeds to insiders
- $80K
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Rapamycin Holdings's investors?
- Rapamycin Holdings's investors include UT Horizon Fund.
- How much funding has Rapamycin Holdings raised?
- Rapamycin Holdings has disclosed $1.4M raised across 1 of its 6 known rounds.
- Where is Rapamycin Holdings headquartered?
- Rapamycin Holdings is headquartered in San Antonio, US.